CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,901 | +220.0% | 127,438 | +134.9% | 0.00% | – |
| Q2 2023 | $594 | +151.7% | 54,241 | +101.1% | 0.00% | – |
| Q1 2023 | $236 | -21.3% | 26,976 | -43.5% | 0.00% | – |
| Q4 2022 | $300 | -98.3% | 47,775 | +845.5% | 0.00% | – |
| Q3 2022 | $18,000 | -95.5% | 5,053 | -96.3% | 0.00% | – |
| Q2 2022 | $398,000 | +206.2% | 134,953 | +222.1% | 0.00% | – |
| Q1 2022 | $130,000 | -77.2% | 41,899 | -75.1% | 0.00% | – |
| Q4 2021 | $570,000 | +448.1% | 168,254 | +493.9% | 0.00% | – |
| Q3 2021 | $104,000 | +160.0% | 28,332 | +215.4% | 0.00% | – |
| Q2 2021 | $40,000 | -84.8% | 8,984 | -84.6% | 0.00% | – |
| Q1 2021 | $264,000 | +104.7% | 58,314 | +157.8% | 0.00% | – |
| Q4 2020 | $129,000 | -43.9% | 22,620 | -28.7% | 0.00% | – |
| Q3 2020 | $230,000 | -44.6% | 31,739 | -73.3% | 0.00% | – |
| Q2 2020 | $415,000 | +103.4% | 118,801 | -13.9% | 0.00% | – |
| Q1 2020 | $204,000 | +36.9% | 138,019 | +83.0% | 0.00% | – |
| Q4 2019 | $149,000 | -96.4% | 75,421 | -90.6% | 0.00% | -100.0% |
| Q3 2019 | $4,111,000 | +43.2% | 802,752 | +100.2% | 0.00% | +50.0% |
| Q2 2019 | $2,871,000 | +243.0% | 400,974 | +536.0% | 0.00% | +100.0% |
| Q1 2019 | $837,000 | +3119.2% | 63,047 | +1783.7% | 0.00% | – |
| Q4 2018 | $26,000 | -95.8% | 3,347 | -94.1% | 0.00% | – |
| Q3 2018 | $624,000 | +975.9% | 56,280 | +1201.9% | 0.00% | – |
| Q2 2018 | $58,000 | -95.0% | 4,323 | -95.1% | 0.00% | -100.0% |
| Q1 2018 | $1,149,000 | -9.2% | 88,387 | -35.7% | 0.00% | 0.0% |
| Q4 2017 | $1,265,000 | +1082.2% | 137,560 | +938.2% | 0.00% | – |
| Q3 2017 | $107,000 | +25.9% | 13,250 | -10.2% | 0.00% | – |
| Q2 2017 | $85,000 | +286.4% | 14,759 | +28.3% | 0.00% | – |
| Q3 2016 | $22,000 | +2100.0% | 11,500 | +784.6% | 0.00% | – |
| Q1 2016 | $1,000 | -92.9% | 1,300 | -45.8% | 0.00% | – |
| Q3 2014 | $14,000 | – | 2,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |